NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan”) today reported that it received a notice (the “5250 Notice”) on November 22, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it was not in compliance with Nasdaq’s continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) (“Rule 5250”) as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the “Q3 Form 10-Q”) in a timely manner.

Read more:
Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq

NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, a novel, central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia.

Original post:
Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia

FLORHAM PARK, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced that on November 21, 2024, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company does not comply with the Nasdaq continued listing requirements due to the Company’s inability to timely file its Quarterly Report on Form 10-Q for the period ended September 30, 2024 (the “Q3 Form 10-Q”). Nasdaq’s notice has no immediate effect on the listing of Celularity’s common stock and warrants, which continue to trade on the Nasdaq Capital Market under the symbols “CELU” and “CELUW,” respectively.

See the original post here:
Celularity Inc. Announces Receipt of Nasdaq Notification

The Company has received initial commitments totaling over $800,000 from strategic investors in connection with the Offering The Company has received initial commitments totaling over $800,000 from strategic investors in connection with the Offering

Link:
Rakovina Therapeutics Announces Private Placement Offering

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 28, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:?HCM; HKEX:?13) today announces that following the contract renewal with the China National Healthcare Security Administration (“NHSA”), the updated National Reimbursement Drug List (“NRDL”) effective on January 1, 2025 will continue to include ORPATHYS® (savolitinib) at the same terms as the current two-year agreement.

Originally posted here:
HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms

Company Records First Commercial Sale of revyve™ Wound Gel Company Records First Commercial Sale of revyve™ Wound Gel

Excerpt from:
Kane Biotech Announces Third Quarter 2024 Financial Results

BARCELONA, Spain, Nov. 29, 2024 (GLOBE NEWSWIRE) -- MEDSIR, a leading company dedicated to advancing independent clinical research in oncology on an international level, participated in the 7th Shanghai International Medical Oncology Symposium (SIMOS) in China, one of the most prestigious academic events in the global oncology field. Through this, the company reaffirms its commitment to scientific advancement, improving breast cancer treatments worldwide, and fostering the exchange of knowledge across regions.

Continue reading here:
MEDSIR, Featured Company at the Shanghai International Medical Oncology Symposium (7th SIMOS)

VANCOUVER, British Columbia, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce that, in response to investor demand, the Company intends to increase the size of the previously announced $1.25 million non-brokered private placement (the “Offering”) to $2.5 million.

More here:
Rakovina Therapeutics Announces Increase in Private Placement Offering to $2.5 Million

Secretome Therapeutics Closes $20.4 Million Financing Round to Advance Cardiomyopathy and Heart Failure Therapies  Business Wire

View original post here:
Secretome Therapeutics Closes $20.4 Million Financing Round to Advance Cardiomyopathy and Heart Failure Therapies - Business Wire

You are the match. How UNC student honored her late grandfather with life-saving effort  Raleigh News & Observer

Read the original:
You are the match. How UNC student honored her late grandfather with life-saving effort - Raleigh News & Observer

scRNA-seq revealed transcriptional signatures of human umbilical cord primitive stem cells and their germ lineage origin regulated by imprinted genes  Nature.com

Read this article:
scRNA-seq revealed transcriptional signatures of human umbilical cord primitive stem cells and their germ lineage origin regulated by imprinted genes...

Atlanta pilot with an aggressive cancer finds lifesaving help from a stranger and a simple test   The Atlanta Journal Constitution

Go here to see the original:
Atlanta pilot with an aggressive cancer finds lifesaving help from a stranger and a simple test - The Atlanta Journal Constitution

Researchers have brought the promise of stem cell therapies closer to reality  The Week

See the original post here:
Researchers have brought the promise of stem cell therapies closer to reality - The Week

How Minaris is Tackling the Scalability Challenge in Cell and Gene Therapy: A Conversation with CEO, Dr. Hiroto Bando  geneonline

Read more from the original source:
How Minaris is Tackling the Scalability Challenge in Cell and Gene Therapy: A Conversation with CEO, Dr. Hiroto Bando - geneonline

MINNEAPOLIS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended September 30, 2024. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET.

See the original post here:
Panbela Provides Business Update and Reports Q3 2024 Financial Results

DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today provided a strategic, financial, and operational update for the third quarter ended September 30, 2024.

See more here:
Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability

Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium (186Re) Obisbemeda for the treatment of patients with leptomeningeal metastases (LM)

Continued here:
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

FORT WORTH, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (Nasdaq: TFFP) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors.

Original post:
TFF Pharmaceuticals Announces It Will Wind Down Operations

- Secures $3.2m in PIPE Financing -- $50m Term Sheet Obtained for Available Financing under Equity Line of Credit -

More:
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio

$13.9 million in gross proceeds raised since the beginning of 2024 extending expected cash runway into mid Q1 2025 and through interim data readout from GRI-0621 Phase 2a biomarker study

See original here:
GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for...